On May 9, 2019 Kitov Pharma Ltd. (the "Company" or "Kitov") (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class combination oncology therapies to overcome tumor drug resistance, increase treatment response rate, and slow tumor progression, reported that its CEO, Isaac Israel, will present at 18th MIXiii-BIOMED Conference and Exhibition, the leading annual international healthcare industry meeting in Israel, to be held on May 14-16, 2019 in Tel Aviv, Israel (Press release, Kitov Pharmaceuticals , MAY 9, 2019, View Source [SID1234536063]). The oral presentation will give an overview of Kitov’s clinical development plans for its oncology candidate NT-219, including disclosing its first indication for a phase 1/2 clinical trial and trial design.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
NT-219 is a first-in-class small molecule dual inhibitor of STAT3 and IRS1/2, with the potential to prevent and overcome drug resistance in various cancer types when used in combination with existing agents.
Presentation Details:
Title: "NT-219, a First-in-class Dual Inhibitor of STAT3 and IRS1/2 is Overcoming Drug Resistance"
Session: Transformative Cancer Therapies
Presenter: Isaac Israel, chief executive officer
Date: Thursday, May 16, 2019
Time: 1:05-1:20 p.m. IST
Location: Hall A, David Intercontinental Hotel
About the MIXiii Biomed Conference
MIXiii-Biomed Conference and Exhibition is the leading annual international healthcare industry meeting in Israel. The conference serves as a meeting point for local and multinational companies, investors, technology transfer experts, university, research scientists, and government representatives. This year, the focus of the conference is expanding to the full spectrum of healthcare: from prevention to rehabilitation and everything in between. Presentations will address diagnosis, monitoring, and treatment domains, and will explore trends and innovations that are shaping the future of the healthcare system to its full extent. Fields to be included are gene editing and gene therapy, transforming medicine, personalized medicine and digital health, transformative cancer therapies, prevention and rehabilitation, new modalities of cell therapies, disruptive and advanced medical devices, and cannabis therapeutics. 18th MIXiii-Biomed will take place May 14-16, 2019, at the David Intercontinental Hotel in Tel Aviv. More information can be found at View Source